Literature DB >> 2719462

Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

S M Smith1, R H Eng, F Tecson-Tumang.   

Abstract

Thirty patients were treated for colonization or for skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Three treatment regimens were evaluated, each progressively more aggressive. Our regimen was 750 mg of ciprofloxacin twice daily for 5 days, the second regimen was 750 mg of ciprofloxacin twice daily for 10 to 14 days, and the final regimen was 750 mg of ciprofloxacin twice daily plus 300 mg of rifampin twice daily for 21 days. It appears that ciprofloxacin alone produced an initial eradication rate in at least one site in 50% of the patients, regardless of whether the treatment was for 5 or up to 14 days. All of the patients with eradication became recolonized within 1 week posttherapy. When rifampin was combined with ciprofloxacin, the eradication rate was 100% when the isolates were susceptible to both agents, and these patients remained free of methicillin-resistant S. aureus at 1-week and 1-month follow-ups.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719462      PMCID: PMC171453          DOI: 10.1128/AAC.33.2.181

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis.

Authors:  M P Pugsley; D L Dworzack; E A Horowitz; T A Cuevas; W E Sanders; C C Sanders
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

2.  In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue.

Authors:  F D Daschner; M Westenfelder; A Dalhoff
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Clinical utility of erythrocyte sedimentation rate and plasma protein analysis in the elderly.

Authors:  J Crawford; M K Eye-Boland; H J Cohen
Journal:  Am J Med       Date:  1987-02       Impact factor: 4.965

5.  Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.

Authors:  M E Mulligan; P J Ruane; L Johnston; P Wong; J P Wheelock; K MacDonald; J F Reinhardt; C C Johnson; B Statner; I Blomquist
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Ciprofloxacin concentrations in human fluids and tissues following a single oral dose.

Authors:  S Esposito; D Galante; D Barba; G D'Errico; A Mazzone; S Montanaro
Journal:  Int J Clin Pharmacol Res       Date:  1987

7.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng; E Berman
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

  8 in total
  19 in total

1.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 4.  Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.

Authors:  R C George; A H Uttley
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

5.  Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.

Authors:  H F Chambers; Q Xiang; L L Chow; C Hackbarth
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 6.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 8.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin.

Authors:  R Darouiche; C Wright; R Hamill; M Koza; D Lewis; J Markowski
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Methicillin-resistant Staphylococcus aureus in Europe.

Authors:  A Voss; D Milatovic; C Wallrauch-Schwarz; V T Rosdahl; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.